Mylan gets FDA green light for generic Canasa
The Food and Drug Administration has approved Mylan’s mesalamine rectal suppository, 1000mg.
Mesalamine rectal suppository is the first generic version of Allergan's Canasa rectal suppository, 1000 mg.
The product is for the treatment of mildly to moderately active ulcerative proctitis.
Mesalamine rectal suppository, 1000 mg had a market value of approximately $263 million for the 12 months ending October 31, 2018, according to IQVIA.
Mesalamine rectal suppository is the first generic version of Allergan's Canasa rectal suppository, 1000 mg.
The product is for the treatment of mildly to moderately active ulcerative proctitis.
Mesalamine rectal suppository, 1000 mg had a market value of approximately $263 million for the 12 months ending October 31, 2018, according to IQVIA.